Cargando…
Cell-free and Concentrated Ascites Reinfusion Therapy for Refractory Ascites in Cirrhosis in Post-marketing Surveillance and the Role of Tolvaptan
OBJECTIVE: Ascites becomes refractory to diuretics in cirrhotic patients, who then require repeated large-volume paracentesis or cell-free and concentrated ascites reinfusion therapy (CART). The objective of this study was to confirm the safety and efficacy of CART, evaluate the actual situations wi...
Autores principales: | Iwasa, Motoh, Ishihara, Tomoaki, Kato, Michio, Isoai, Ayako, Kobayashi, Ryosuke, Torii, Naoko, Soneda, Noriko, Takei, Yoshiyuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Society of Internal Medicine
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6875447/ https://www.ncbi.nlm.nih.gov/pubmed/31292400 http://dx.doi.org/10.2169/internalmedicine.3091-19 |
Ejemplares similares
-
Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) in refractory ascites: Post-marketing surveillance results
por: Hanafusa, Norio, et al.
Publicado: (2017) -
Serum Copeptin and Zinc-α2-glycoprotein Levels Are Novel Biomarkers of Tolvaptan Treatment in Decompensated Cirrhotic Patients with Ascites
por: Shigefuku, Ryuta, et al.
Publicado: (2021) -
Tolvaptan for the Treatment of Refractory Ascites
por: Kurosaki, Masayuki, et al.
Publicado: (2016) -
Weaning from concentrated ascites reinfusion therapy for refractory ascites by SGLT2 inhibitor
por: Miyamoto, Yasunori, et al.
Publicado: (2021) -
Ultrastructural observation of filtration membrane in cell‐free and concentrated ascites reinfusion therapy for malignant ascites
por: Koga, Kenichi, et al.
Publicado: (2021)